Antimicrobial activity of daptomycin and selected comparators tested against bloodstream Staphylococcus aureus isolates from hemodialysis patients

Antimicrobial activity of daptomycin and selected comparators tested against bloodstream Staphylococcus aureus isolates from hemodialysis patients

Author Sader, Helio Silva Autor UNIFESP Google Scholar
Fritsche, Thomas R. Google Scholar
Jones, Ronald N. Google Scholar
Institution JMI Labs
Universidade Federal de São Paulo (UNIFESP)
Tufts Univ
Abstract Background: Patients on long-term hemodialysis are at a significantly higher risk for catheter-related bloodstream infections (BSI) than the general population. These infections are generally caused by Gram-positive organisms, especially Staphylococcus aureus. in the present study, we evaluated the antimicrobial susceptibility patterns of S. aureus causing BSI in dialysis patients compared to those causing BSI in other patient populations.Methods: the potencies of daptomycin and various comparator agents were evaluated by reference broth microdilution methods for S. aureus bloodstream isolates from dialysis patients (606 strains) in 43 hospitals in North America and Europe. Susceptibility patterns for the dialysis isolate set were compared to those S. aureus causing BSI in other patient populations in the same hospitals and time period.Results: Daptomycin was highly potent against S. aureus causing bacteremia in dialysis patients (MIC(50)/MIC(90), 0.25/0.5 mu g/ml). Vancomycin (MIC(50)/MIC(90), 1/1 mu g/ml) and linezolid (MIC(50)/MIC(90), 2/2 mu g/ml) showed similar potency, and overall susceptibility rates for the three antibiotics were 99.8-100.0% susceptible. Linezolid and vancomycin were four- to eight-fold less potent than daptomycin.Conclusions: the overall susceptibility patterns of S. aureus strains from dialysis patients were very similar to those of non-dialysis patients. (c) 2008 International Society for Infectious Diseases. Published by Elsevier B.V. All rights reserved.
Keywords Hemodialysis
Daptomycin
Staphylococcus aureus
Catheter infection
Bacteremia
Bloodstream infection
Language English
Sponsor Cubist Pharmaceuticals, Inc.
AB BIODISK
Abbott
API
Arpida
Astellas
AstraZeneca
Avexa
Bayer
bioMerieux
Cadence
Cempra
Cerexa
Chiron
Cornerstone
Cubist
Daiichi
Elan
Elanco
Enanta
GlaxoSmithKline
Johnson Et Johnson (Ortho McNeil)
Merck
Novartis
Optimer
Ordway
Osmotics
Pacific Beach
Peninsula
Pfizer
Protez
Replidyne
Schering-Plough
Sequoia
Shionogi
Theravance
TREK Diagnostics
ViroPharma
Wyeth
Date 2009-03-01
Published in International Journal of Infectious Diseases. Oxford: Elsevier B.V., v. 13, n. 2, p. 291-295, 2009.
ISSN 1201-9712 (Sherpa/Romeo, impact factor)
Publisher Elsevier B.V.
Extent 291-295
Origin http://dx.doi.org/10.1016/j.ijid.2008.07.006
Access rights Open access Open Access
Type Article
Web of Science ID WOS:000264707200028
URI http://repositorio.unifesp.br/handle/11600/31334

Show full item record




File

Name: WOS000264707200028.pdf
Size: 128.1Kb
Format: PDF
Description:
Open file

This item appears in the following Collection(s)

Search


Browse

Statistics

My Account